Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Promising interim results announced for SU-5416 phase I trial

Nov. 10, 1998

Two major clinical studies demonstrate chemo- and radioprotective activity of amifostine

Nov. 10, 1998

Ribozyme initiates phase I clinical trials of Angiozyme

Nov. 9, 1998

GBC-590 effective in murine model of treatment-resistant pancreatic cancer

Nov. 9, 1998

Progen commences phase I trials of PI-88 in the U.K.

Nov. 6, 1998

Phase II trials demonstrate ability of Onco TCS to reduce tumor size in NHL patients

Nov. 6, 1998

Chinese researchers synthesize cytotoxic alkaloid derivative HH-07A

Nov. 6, 1998

Licensing opportunity from the NIH: method of inhibiting HGF/SF cleavage, activation

Nov. 5, 1998

Irreversible inactivators of EGF receptor TK hold promise as antitumor agents

Nov. 5, 1998

NAALADase inhibitors now reported to be useful for prostate cancer; patents issued

Nov. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...